Advertisement

Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse

      Purpose

      To determine the efficacy of a combined approach of radiotherapy (RT) plus 2-year androgen suppression (AS) as salvage treatment for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP).

      Methods and Materials

      Seventy-five patients with PSA relapse after RP were treated with salvage RT plus 2-year AS, as per a pilot, prospective study. AS started within 1 month after completion of salvage RT and consisted of nilutamide for 4 weeks and buserelin acetate depot subcutaneously every 2 months for 2 years. Relapse-free rate including freedom from PSA relapse was estimated using the Kaplan-Meier method. PSA relapse was defined as a PSA rise above 0.2 ng/mL with two consecutive increases over a minimum of 3 months. A Cox regression analysis was performed to evaluate prognostic factors for relapse.

      Results

      Median age of the cohort was 63 years at the time of salvage RT. Median follow-up from salvage RT was 6.4 years. All achieved initially complete PSA response (< 0.2) with the protocol treatment. Relapse-free rate including the freedom from PSA relapse was 91.5% at 5 years and 78.6% at 7 years. Overall survival rate was 93.2% at both 5 and 7 years. On Cox regression analysis, pT3 stage and PSA relapse less than 2 years after RP were significant prognostic factors for relapse.

      Conclusion

      The combined treatment of salvage RT plus 2-year AS yielded an encouraging result for patients with PSA relapse after RP and needs a confirmatory study.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Medini D.
        • Medini I.
        • Reddy P.K.
        • et al.
        Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy.
        Cancer. 1996; 78: 1254-1259
        • Crane C.H.
        • Rich T.A.
        • Read P.W.
        • et al.
        Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation.
        Int J Radiat Oncol Biol Phys. 1997; 39: 681-686
        • Do T.
        • Parker R.G.
        • Do C.
        • et al.
        Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
        Cancer J Sci Am. 1998; 4: 324-330
        • Cadeddu J.A.
        • Partin A.W.
        • DeWeese T.L.
        • et al.
        Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.
        J Urol. 1998; 59: 173-178
        • Schild S.E.
        Radiation therapy after prostatectomy: Now or later?.
        Semin Radiat Oncol. 1998; 8: 132-139
        • Leventis A.K.
        • Shariat S.F.
        • Kattan M.W.
        • et al.
        Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy.
        J Clin Oncol. 2001; 19: 1030-1039
        • Stephenson A.J.
        • Shariat S.F.
        • Zelefsky M.J.
        • et al.
        Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
        JAMA. 2004; 291: 1325-1332
        • Pazona J.F.
        • Han M.
        • Hawkins S.A.
        • et al.
        Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates.
        J Urol. 2005; 174: 1282-1286
        • Buskirk S.J.
        • Pisansky T.M.
        • Schild S.E.
        • et al.
        Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: Evaluation of prognostic factors and creation of a prognostic scoring system.
        J Urol. 2006; 176: 985-990
        • Choo R.
        • Hruby G.
        • Hong J.
        • et al.
        The (in)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence following radical prostatectomy.
        Int J Rad Oncol Biol Phys. 2002; 53: 269-276
        • De Meerleer G.
        • Fonteyne V.
        • Meersschout S.
        • et al.
        salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy.
        Radiother Oncol. 2008; 89: 205-213
        • Pearce A.
        • Choo R.
        • Danjoux C.
        • et al.
        Effect of combined treatment of salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 2006; 65: 78-83
        • Pearse M.
        • Choo R.
        • Danjoux C.
        • et al.
        Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with PSA relapse or local recurrence after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 2008; 72: 792-798
        • Kaplan E.L.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        Am Stat Assoc J. 1958; 53: 457-481
        • Cox D.R.
        Regression models and life tables.
        J Royal Stat Soc. 1972; B34: 187-220
        • Wu J.J.
        • King S.C.
        • Montana G.S.
        • et al.
        The efficacy of post prostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen.
        Int J Radiat Oncol Biol Phys. 1995; 35: 317-323
        • Forman J.D.
        • Meetze K.
        • Pontes E.
        • et al.
        Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level.
        J Urol. 1997; 158: 1436-1440
        • Katz M.S.
        • Zelefsky M.J.
        • Venkatraman E.S.
        • et al.
        Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.
        J Clin Oncol. 2003; 21: 483-489
        • Tiguert R.
        • Rigaud J.
        • Lacombe L.
        • et al.
        Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
        J Urol. 2003; 170: 447-450
        • Anscher M.S.
        • Clough R.
        • Dodge R.
        Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years.
        Int J Radiat Oncol Biol Phys. 2000; 48: 369-375
        • Macdonald O.K.
        • D'Amico A.V.
        • Sadetsky N.
        • et al.
        Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: From the CaPSURE database.
        Urol Oncol. 2008; 26: 271-275
        • Trock B.J.
        • Han M.
        • Freedland S.J.
        • et al.
        Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
        JAMA. 2008; 299: 2760-2769
        • Stephenson A.J.
        • Scardino P.T.
        • Kattan M.W.
        • et al.
        Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
        J Clin Oncol. 2007; 25: 2035-2041

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.